1958 : Debut of SQUARE Pharma as a Partnership Firm.
1964 : Converted into a Private Limited Company.
1974 : Technical Collaboration with Janssen Pharmaceuticals, Belgium, a subsidiary of Johnson and Johnson International, USA.
1982 : Licensing Agreement signed with F. Hoffman-La Roche & Co Ltd., Switzerland.
1985 : Achieved market-leadership in the pharmaceutical market of Bangladesh among all national and multinational companies.
1987 : Pioneer in pharmaceutical export from Bangladesh.
1991 : Converted into a Public Limited Company
1994 : Initial Public Offering of shares of SQUARE Pharmaceuticals Ltd.
1995 : Chemical Division of SQUARE Pharmaceuticals Ltd. starts production of Active Pharmaceutical Ingredients (API).
1997 : Won the National Export trophy for exporting pharmaceuticals.
1998 : Agro-chemicals & Veterinary Products division of SQUARE Pharmaceuticals starts its operation.
2001 : US FDA/UK MCA standard new pharmaceutical factory goes into operation built under the supervision of Bovis Lend Lease, UK.
2004 : SQUARE enlisted as UNICEF's global supplier.
2005 : New State-of-the-Art SQUARE Cephalosporins Ltd. goes into operation; built under the supervision of TELSTAR S.A. of Spain as per US FDA/ UK MHRA requirements.
2007 : SQUARE Pharmaceuticals Ltd., Dhaka Unit gets the UK MHRA approval.
2009 : Starts manufacturing of insulin maintaining quality standards of US FDA & UK MHRA. Dedicated hormone & steroid products manufacturing facility complying with the current Good Manufacturing Practice (cGMP) of WHO, US FDA & UK MHRA starts operation.
2012 : SQUARE Pharmaceuticals Ltd., Dhaka Unit and SQUARE Cephalosporins Ltd. get the Therapeutic
Goods Administration(TGA) of Australia approval.
2015 : PAI (Pre Approval Inspection) by US FDA was successful for Dhaka Site’s solid dosage unit.
: WHO approved Square’s GMP.